Literature DB >> 1557245

Light and retinopathy of prematurity: does retinal location offer a clue?

A R Fielder1, J Robinson, D E Shaw, Y K Ng, M J Moseley.   

Abstract

Nursery illumination has been implicated in the pathogenesis of retinopathy of prematurity (ROP), although the results of recent studies are conflicting. The data base for this article is a prospective ROP study on 607 infants of birth weight less than or equal to 1700 g including 35 larger siblings from multiple births when 1 infant fulfilled the birth weight criteria. Retinopathy commences preferentially in the nasal retina of the most immature neonate and is less likely to develop, or its onset is delayed, in the superior and inferior regions. These findings cannot be fully accounted for by regional vascular and neuroanatomical variations. Radiometric and physiological evidence suggests that the very immature neonate, most at risk of developing severe ROP, receives the greatest retinal irradiance. Furthermore, ROP commences in the areas of the retina receiving the highest light dose, and its onset is either retarded or inhibited in the darker retinal regions. Further studies are required to determine whether early exposure to light is a factor in the development of ROP. If a causal relationship is proven, here at least is one modality that can easily and immediately be controlled.

Entities:  

Mesh:

Year:  1992        PMID: 1557245

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  3 in total

1.  Visual impairment in very low birthweight children.

Authors:  A Powls; N Botting; R W Cooke; G Stephenson; N Marlow
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-03       Impact factor: 5.747

Review 2.  Retinopathy of prematurity.

Authors:  E Bossi; F Koerner
Journal:  Intensive Care Med       Date:  1995-03       Impact factor: 17.440

3.  Retinopathy of prematurity: A systematic review of the literature.

Authors: 
Journal:  Paediatr Child Health       Date:  1998-05       Impact factor: 2.253

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.